APA

Smith N., Longo N., Levert K., Hyland K. & Blau N. (20191107). Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. : Molecular genetics and metabolism.

Chicago

Smith Neil, Longo Nicola, Levert Keith, Hyland Keith and Blau Nenad. 20191107. Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. : Molecular genetics and metabolism.

Harvard

Smith N., Longo N., Levert K., Hyland K. and Blau N. (20191107). Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. : Molecular genetics and metabolism.

MLA

Smith Neil, Longo Nicola, Levert Keith, Hyland Keith and Blau Nenad. Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers. : Molecular genetics and metabolism. 20191107.